Intrexon Corp (XON) Receives Average Recommendation of “Hold” from Brokerages

Shares of Intrexon Corp (NYSE:XON) have received a consensus recommendation of “Hold” from the nine analysts that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $38.50.

Several equities analysts have recently commented on XON shares. Zacks Investment Research downgraded shares of Intrexon from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Northland Securities restated a “buy” rating and issued a $21.00 price target on shares of Intrexon in a research report on Friday, November 10th. Stifel Nicolaus boosted their price target on shares of Intrexon from $39.00 to $57.00 and gave the stock a “buy” rating in a research report on Friday, November 10th. ValuEngine cut shares of Intrexon from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Finally, Bank of America reduced their price target on shares of Intrexon from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, November 10th.

In other Intrexon news, CEO Randal J. Kirk purchased 1,000,000 shares of Intrexon stock in a transaction that occurred on Friday, January 19th. The shares were bought at an average price of $12.50 per share, for a total transaction of $12,500,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 56.30% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Intrexon by 3.4% during the second quarter. Vanguard Group Inc. now owns 4,433,879 shares of the biotechnology company’s stock valued at $106,811,000 after acquiring an additional 147,517 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Intrexon by 5.6% during the second quarter. Goldman Sachs Group Inc. now owns 152,576 shares of the biotechnology company’s stock valued at $3,675,000 after acquiring an additional 8,148 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Intrexon by 493.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,258 shares of the biotechnology company’s stock valued at $271,000 after acquiring an additional 11,854 shares during the last quarter. Trellus Management Company LLC bought a new position in Intrexon during the third quarter valued at $475,000. Finally, Dynamic Technology Lab Private Ltd increased its position in Intrexon by 127.0% during the third quarter. Dynamic Technology Lab Private Ltd now owns 24,640 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 13,783 shares during the last quarter. Institutional investors and hedge funds own 75.10% of the company’s stock.

Intrexon (NYSE XON) traded up $0.51 during mid-day trading on Tuesday, hitting $13.16. 711,843 shares of the stock traded hands, compared to its average volume of 2,286,994. Intrexon has a 1 year low of $10.26 and a 1 year high of $26.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.05 and a quick ratio of 1.85. The stock has a market capitalization of $1,640.00, a P/E ratio of -11.67 and a beta of 1.40.

COPYRIGHT VIOLATION NOTICE: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/13/intrexon-corp-xon-receives-average-recommendation-of-hold-from-brokerages.html.

Intrexon Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Analyst Recommendations for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply